Novel Drug Relieves Pruritus Associated With Chronic Kidney Disease
Difelikefalin, a peripherally restricted, selective kappa opioid receptor agonist, relieved moderate to severity itching in patients with stage 3 to 5 CKD significantly better than placebo in a phase 2 trial.